Question 1

What is Ublituximab?

Accepted Answer

Ublituximab is a Other.

Question 2

How often does Ublituximab appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 6 articles.

Question 3

When was Ublituximab first tracked by Ergen?

Accepted Answer

First tracked on Jan 13, 2026.

Question 4

When was Ublituximab last mentioned in news?

Accepted Answer

Last active on Mar 09, 2026.

Question 5

What is Ublituximab's current news sentiment?

Accepted Answer

Aggregate sentiment score: 80 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Ublituximab in global news coverage?

Accepted Answer

Attention score of 6, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving Ublituximab?

Accepted Answer

TG Therapeutics 2025 Earnings and BRIUMVI Data (Jan 13, 2026, 6 articles).

Question 8

How did the "TG Therapeutics 2025 Earnings and BRIUMVI Data" event impact Ublituximab?

Accepted Answer

Ublituximab, a key product for TG Therapeutics, demonstrated significant year-over-year growth in U.S. net revenue and expanded global availability. Positive long-term efficacy and safety data were published, and new studies are underway to further enhance its market potential.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.